In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report), with a price target of $8.00. The company's shares closed last Friday at $1.02, close to its 52-week low of $0.85. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -44.3% and a 8.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Oramed Pharmaceuticals. Currently, the analyst consensus on Oncternal Therapeutics is a Strong Buy with an average price target of $8.33, implying a 678.5% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-oncternal-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral